Zacks Investment Research upgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a hold rating to a buy rating in a research note released on Wednesday morning. They currently have $9.25 price target on the biotechnology company’s stock.
According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
Separately, BidaskClub raised shares of Seres Therapeutics from a sell rating to a hold rating in a report on Saturday, February 24th. Two equities research analysts have rated the stock with a sell rating and nine have assigned a buy rating to the company. Seres Therapeutics currently has an average rating of Buy and an average price target of $17.89.
Shares of Seres Therapeutics opened at $7.77 on Wednesday, according to MarketBeat. Seres Therapeutics has a 1 year low of $6.65 and a 1 year high of $17.42. The firm has a market cap of $339.45 million, a PE ratio of -3.52 and a beta of 0.49. The company has a debt-to-equity ratio of 0.85, a current ratio of 3.60 and a quick ratio of 3.60.
Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings results on Wednesday, May 9th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.06. Seres Therapeutics had a negative net margin of 277.79% and a negative return on equity of 150.44%. The company had revenue of $3.97 million during the quarter, compared to the consensus estimate of $3.00 million. analysts anticipate that Seres Therapeutics will post -2.52 earnings per share for the current year.
In related news, insider John G. Aunins sold 14,279 shares of the company’s stock in a transaction dated Wednesday, April 25th. The shares were sold at an average price of $7.58, for a total value of $108,234.82. Following the completion of the sale, the insider now owns 184,485 shares of the company’s stock, valued at $1,398,396.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 41.90% of the company’s stock.
Hedge funds have recently bought and sold shares of the stock. Arrowstreet Capital Limited Partnership acquired a new stake in Seres Therapeutics in the fourth quarter worth about $143,000. Wells Fargo & Company MN lifted its holdings in Seres Therapeutics by 107.2% in the fourth quarter. Wells Fargo & Company MN now owns 29,183 shares of the biotechnology company’s stock worth $296,000 after purchasing an additional 15,097 shares during the period. Lakeview Capital Partners LLC acquired a new stake in Seres Therapeutics in the fourth quarter worth about $346,000. Virtus Fund Advisers LLC acquired a new stake in Seres Therapeutics in the fourth quarter worth about $358,000. Finally, Two Sigma Advisers LP lifted its holdings in Seres Therapeutics by 153.6% in the fourth quarter. Two Sigma Advisers LP now owns 35,500 shares of the biotechnology company’s stock worth $360,000 after purchasing an additional 21,500 shares during the period. 78.93% of the stock is owned by institutional investors and hedge funds.
About Seres Therapeutics
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.